Key Elemental Differences causing Cisplatin Induced Hearing Loss
Session Number
Project ID: MEDH 04
Advisor(s)
Dr. Claus-Peter Richter, Department of Otolaryngology, Feinberg School of Medicine, Northwestern University
Discipline
Medical and Health Sciences
Start Date
20-4-2022 10:25 AM
End Date
20-4-2022 10:40 AM
Abstract
Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (i.e. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors (DrugBank, 2021). Cisplatin can cause hearing loss in the cochlea, which is a result of some of the cancer therapies that happen in hospitals. In this study three experimental groups were looked at, Cisplatin alone, Cisplatin in conjunction with Honokiol, and Honokiol by itself. Honokiol is used due to the possibility that the drug can provide effects to limit cisplatin induced hearing loss by inhibiting the production of ROS. Samples of the three test groups were taken and scanned at Argonne National Laboratory using an 8-BM photon beam. A comparison using the Image J program reveals the concentration of elements located within the inner ear. A closer look at Cisplatin with Honokiol revealed significant differences in Platinum levels when compared to Cisplatin alone and reports of significantly less hearing loss is recorded with these patients. Cisplatin levels of Platinum reveal ototoxicity and with a complement of Honokiol can bind to platinum and significantly reduce the ototoxicity present
Key Elemental Differences causing Cisplatin Induced Hearing Loss
Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (i.e. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors (DrugBank, 2021). Cisplatin can cause hearing loss in the cochlea, which is a result of some of the cancer therapies that happen in hospitals. In this study three experimental groups were looked at, Cisplatin alone, Cisplatin in conjunction with Honokiol, and Honokiol by itself. Honokiol is used due to the possibility that the drug can provide effects to limit cisplatin induced hearing loss by inhibiting the production of ROS. Samples of the three test groups were taken and scanned at Argonne National Laboratory using an 8-BM photon beam. A comparison using the Image J program reveals the concentration of elements located within the inner ear. A closer look at Cisplatin with Honokiol revealed significant differences in Platinum levels when compared to Cisplatin alone and reports of significantly less hearing loss is recorded with these patients. Cisplatin levels of Platinum reveal ototoxicity and with a complement of Honokiol can bind to platinum and significantly reduce the ototoxicity present